Trial · NCT02704364
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in ALP was assessed in participants with available data in the Full Analysis Set. | International units/Liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent change from baseline in ALP was assessed in participants with available data in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean rate of change in ALP was assessed in participants with available data in the Full Analysis Set . | U/L/Week | MEAN |
| SECONDARY | Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean changes from baseline in aspartate aminotransferase and alanine aminotransferase were assessed in participants with available data in the Full Analysis Set. | units/liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent changes from baseline in aspartate aminotransferase and alanine aminotransferase were assessed in participants with available data in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in Bilirubin (Direct and Total) in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in bilirubin (total and direct) was assessed in participants with available data in the Full Analysis Set. | micromole/liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Bilirubin (Direct and Total) in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent changes from baseline in bilirubin (total and direct) were assessed in participants with available data in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in Gamma Glutamyl Transferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in gamma glutamyl transferase was assessed in participants with available data in the Full Analysis Set. | units/liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Gamma Glutamyl Transferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent change from baseline in gamma glutamyl transferase was assessed in participants with available data in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in Cholesterol Levels in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in cholesterol levels were assessed in participants with available data in the Full Analysis Set. | millimole/liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Cholesterol Levels in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent change from baseline in cholesterol levels were assessed in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in 25-Hydroxyvitamin D in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in 25-Hydroxyvitamin D was assessed in the Full Analysis Set. | nmol/Liter | MEAN |
| SECONDARY | Mean Percent Change From Baseline in 25-Hydroxyvitamin D in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent change from baseline in 25-Hydroxyvitamin D was assessed in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in Prothrombin International Normalized Ratio in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in Prothrombin was assessed in participants with available data in the Full Analysis Set. | International normalized ratio | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Prothrombin International Normalized Ratio in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean percent change from baseline in Prothrombin was assessed in participants with available data in the Full Analysis Set. | percent change | MEAN |
| SECONDARY | Mean Change From Baseline in Calprotectin in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in Calprotectin was assessed in participants with available data in the Full Analysis Set. | microgram/gram | MEAN |
| SECONDARY | Mean Change From Baseline in Enhanced Liver Fibrosis Score in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Mean change from baseline in Enhanced Liver Fibrosis Score was assessed in the Full Analysis Set. | units on a scale | MEAN |
| SECONDARY | Severity of Inflammatory Bowel Disease-Associated Intestinal Symptoms in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Severity of inflammatory bowel disease-associated intestinal symptoms were assessed in the Full Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02704364/outcomes